Atea Pharmaceuticals Achieves C-BEYOND Phase 3 Clinical Endpoints and Secures $200 Million Credit Facility
AVIR Atea Pharmaceuticals Inc
$4.41 +2.32%
View chart & analysis → - 1Atea Pharmaceuticals met the primary and secondary endpoints of the C-BEYOND Phase 3 clinical trial in the third quarter of 2026.
- 2Atea Pharmaceuticals secured a $200 million credit facility from Hercules Capital.
- 3An amount of $65 million was drawn by Atea Pharmaceuticals upon settlement on November 6.
So what's the key point?
The drug trial being conducted by Atea Pharmaceuticals successfully met its planned goals. The company also secured $200 million in funding.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.